Morgan Stanley 18th Annual Virtual Global Healthcare Conference
Sep 14, 2020 10:30 AM EDT
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>
SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data will be presented at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting 2020 taking place online from September 30, 2020 – October 6,
Grant s Suppor t Community Engagement for Patient Advocacy Organization s Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 1 3 th , 2020 SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK)
Company Advances Second Cardiac Myosin Inhibitor SOUTH SAN FRANCISCO, Calif. , Sept. 23, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 placebo-controlled, single ascending dose clinical study of CK-3772271
Trial Proceeding Toward Conclusion, Topline Results Expected in Q4 2020 SOUTH SAN FRANCISCO, Calif. , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes T hrough I mproving C
